The document highlights the World Health Organization's (WHO) announcement of the first prequalification of an Ebola vaccine on November 12, 2019. This decision is pivotal for UN agencies and Gavi, the Vaccine Alliance, as it confirms that the rVSV-ZEBOV-GP Ebola vaccine, produced by Merck, meets WHO's standards for quality, safety, and efficacy. The prequalification is especially beneficial for developing countries, like African nations most vulnerable to Ebola, where regulatory capacities are limited. The vaccine has been used in the Democratic Republic of the Congo (DRC) with an efficacy of 97.5%. Approximately 250,000 individuals have received the vaccine, showcasing its acceptance and effectiveness. The vaccine's availability is expected to be a game-changer in the fight against Ebola, especially given the devastating impact of past outbreaks.
You can submit a specific query to QUAMED experts by clicking on the button below. We will send relevant answers directly to your mailbox.
Submit Query
The information provided on this Web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government.
ISO 9001:2015 - FS766975
© 2024 - QUAMED
Content of this site is licensed under a Creative Commons License- BY Attribution